Tuesday, September 30, 2014 Last update: 11:03 AM
FreshNews.com - Tech News = Large & Small Companies (Many you've never heard of) Since 1996

CORRECTED DATE FOR Q2 CONFERENCE CALL: Compugen Second Quarter 2014 Conference Call Scheduled for Wednesday, August 6, 2014 at 10:00 AM EDT

Companies mentioned in this article: Compugen Ltd.

TEL AVIV, Israel -- (BUSINESS WIRE) -- Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EDT on Wednesday, August 6, 2014 to review the second quarter 2014 results. The quarterly results will be released on the Company’s website (www.cgen.com), prior to the conference call. A previous release stating August 5 as the date for the call was in error.

To access the conference call, please dial 1-888-281-1167 from the US, or + 972-3-918-0610 internationally. The call will also be available via live webcast located at the following link.

A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-877-456-0009 from the US or +972-3-925-5925 internationally. The replay will be available through August 8, 2014.

About Compugen

Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. Compugen’s wholly-owned U.S. subsidiary located in South San Francisco is developing oncology and immunology monoclonal antibody therapeutic candidates against its drug targets. For additional information, please visit Compugen's corporate website at www.cgen.com.


Copyright © Business Wire 2014
Contact:

Compugen Ltd.
Tsipi Haitovsky
Global Media Liaison
+972-52-598-9892
tsipih@cgen.com